MLA Diagnostics

A revolutionary prognostic test for early stage melanoma


Melanoma is the most deadly form of skin cancer. After diagnosis it is vital to know the risk of whether the disease is likely to spread. Prognostic information is important at this stage. Unfortunately current prognostic tools often classify patients as low risk but these patients still progress to metastatic disease and die without getting the treatment they needed.


MLA Diagnostics’ innovative product is an in vitro diagnostic (IVD) method that is able to determine melanoma patients with low or high metastatic risk. Performed by the pathologist, this test provides more insight on a patients’ expected outcome and will enable a different course of treatment (more or less intensive).

News from MLA Diagnostics

KWF project to begin!

MLA Dx is pleased to share the successful KWF Kankerbestrijding project grant. In this project we will support project lead Prof. Dr. Manon van Engeland

Read More →

What a way to start 2022!

This month we celebrate Teaming up with Maastricht University in a TKI academic project for the discovery of clinically relevant methylation markers. A Rabobank Innovation

Read More →

Contact Us

Visit us in Maastricht

Where research and entrepreneurship come together